News
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...
Researchers at the Pennington Biomedical Research Center have found new clues about how the drug tirzepatide, also known by ...
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.
Board Certified in Endocrinology, Diabetes, and Metabolism and Internal Medicine, Dr. Caveney leads IQVIA’s Obesity, ...
Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...
Eli Lilly (LLY) will report Q1 results on Thursday. Analysts expect in line results with focus on tirizepatide and obesity franchise.
Verywell Health on MSN12d
Zepbound Helps Keep Weight Off for 3 Years, Study FindsA pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...
The Food and Drug Administration (FDA) has also approved Zepbound to help with sleep apnea in people with obesity. A valid prescription from a licensed healthcare provider is needed to get ...
The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback